A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin. Side effects and tolerability will be documented. Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels. The study will last up to 18 weeks and may include 18 visits for each participant.

Inclusion Criteria:Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) and treated with basal insulin and up to one non-insulin anti-hyperglycemic medication.Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)Have received a stable daily dose of basal insulin at screeningHave hemoglobin A1c (HbA1c) greater than or equal to (≥)6.5 percent (%) and less than or equal to (≤)10.0% at screeningNative Chinese participant who has both parents and all 4 grandparents of Chinese origin.Exclusion Criteria:Have a diagnosis of type 1 diabetes mellitus or latent autoimmune diabetesHave a history of ketoacidosis or hyperosmolar state/coma episode or severe hypoglycemia or hypoglycemia unawareness in the 6 months prior to screeningAre receiving insulin other than once daily basal insulinHave any active infectious or serious disease or major organs insufficiencyWomen who are pregnant or lactating